Patents Issued in November 1, 2016
  • Patent number: 9480661
    Abstract: An orally disintegrating tablet which can be chewed or disintegrated by contact with saliva and containing weight-loss drugs for weight control in humans, especially in children and adolescents, is disclosed.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: November 1, 2016
    Assignee: Alpex Pharma S.A.
    Inventors: Federico Stroppolo, Shahbaz Ardalan
  • Patent number: 9480662
    Abstract: The present invention provides topical compositions and methods for administering tamoxifen citrate while minimizing the incidence and or severity of adverse drug experiences associated with tamoxifen therapy. In one aspect, these compositions and methods provide a lower plasma concentration of tamoxifen metabolites, such as 4-hydroxytamoxifen and N-desmethyltamoxifen, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient tamoxifen as the sole active agent to benefit a subject with tamoxifen therapy.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: November 1, 2016
    Inventors: Janet A. Chollet, Fred H. Mermelstein
  • Patent number: 9480663
    Abstract: Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: November 1, 2016
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Mark S. Fineman, Nigel R. A. Beeley
  • Patent number: 9480664
    Abstract: Compositions containing one or more COX inhibitors in combination with one or more antagonists of 20-HETE (20-hydroxyeicosatetraeonic acid), and optionally a pharmaceutically acceptable excipient are provided. Preferred compositions include rofecoxib in combination with HET0016. The compositions have reduced side effects due to COX inhibitors. Methods for treating or inhibiting cancer using the disclosed compositions are also provided.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Augusta University Research Institute, Inc.
    Inventor: Mong-Heng Wang
  • Patent number: 9480665
    Abstract: Provided herein are methods for treating pain such as acute or chronic pain or fever in subject without risking hepatotoxicity. The subject may be at risk of hepatotoxicity if administrated an acetaminophen monomer. The method includes administering a pharmaceutical composition containing an acetaminophen dimer compound, wherein the phenolic hydroxyl groups of two acetaminophen compounds are linked via an ethylene spacer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: November 1, 2016
    Assignee: ORPHOMED, INC.
    Inventor: Nikhilesh Nihala Singh
  • Patent number: 9480666
    Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: November 1, 2016
    Inventors: Tobias Deuse, Sonja Schrepfer
  • Patent number: 9480667
    Abstract: An NSAID formulation for encapsulation into a soft gel capsule with increased stability, concentration and bioavailability of the NSAID. The preferred NSAIDS are naproxen, ibprofen, indomethacin and diclofenac, which are provided in both an acidic and basic form in the fill formulation. The pH values of fill formulations may be adjusted without additional process steps. A process for increasing the achievable concentration of an NASAID pharmaceutical ingredient in a fill composition for dosage units is also provided. The highly concentrated NASAID formulation permits a reduction in the fill volume or dosage unit size or an increase in concentration of the NSAID in each dosage it.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: November 1, 2016
    Assignee: ACCUCAPS INDUSTRIES LIMITED
    Inventors: John Lopez, Peter Draper, Sankalp Vashishtha, Nancy Klassen, Christina Armstrong
  • Patent number: 9480668
    Abstract: The present invention provides a blood flow promoting agent containing citrulline or a salt thereof and capsaicin or capsaicinoids as active ingredients, which is safe even by long-term administration, a food with health claims and a functional food affording such action, particularly, a blood flow promoting agent exhibiting an effective vasodilatory action of capsaicin at a low dose free of irritant property, which can be applied to improvement of athletic performance exhibited in relation to peripheral vasodilatation, suppression of fat accumulation, improvement of skin quality, as well as securing blood circulation in ischemic disease and the like, relaxation of blood vessel biased to coarctation due to advancing age, lifestyle-related diseases and the like, prophylaxis of arteriosclerosis, and prophylaxis of stiff neck, feeling of cold, erectile dysfunction, thrombosis and the like due to blood flow disorder.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: November 1, 2016
    Assignee: Kyowa Hakko Bio Co., Ltd.
    Inventors: Masahiko Morita, Ayako Kamimura, Yoshinori Kobayashi
  • Patent number: 9480669
    Abstract: Disclosed is a method comprising the administration of a 3% amino acid and 3% glycerin solution for the use of prevention and disruption of bacterial biofilms. Also disclosed is method comprising the administration of L-cysteine 0.4 g per 100 ml for the prevention and destruction of fungal biofilms.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: November 1, 2016
    Assignee: The Regents of The University of California
    Inventors: Thomas Benedict Bryan, Clarissa J. Nobile
  • Patent number: 9480670
    Abstract: A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: November 1, 2016
    Assignee: Nestec S.A.
    Inventors: Catherine Mace, Olivier Aprikian
  • Patent number: 9480671
    Abstract: A nutritional composition comprising a significant amount of arachidonic acid (ARA) is described. Such nutritional composition is particularly suitable for infants below the age of 3 years, preferably between birth and 12 months of life. The composition can be used to reduce the risk of developing overweight/obesity and/or insulin resistance later in life.
    Type: Grant
    Filed: April 9, 2013
    Date of Patent: November 1, 2016
    Assignee: Nestec S.A.
    Inventors: Catherine Mace, Olivier Aprikian
  • Patent number: 9480672
    Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: November 1, 2016
    Assignee: LION CORPORATION
    Inventors: Hiroki Takenaka, Yasuharu Ishihara, Naoki Ichiyanagi, Misato Koakutsu, Kei Kurita
  • Patent number: 9480673
    Abstract: The present invention provides a method and composition for treating a neurodegenerative disease. In particular, the present invention provides a method and composition to increase DJ-1 gene expression or DJ-1 protein activity to treat a neurodegenerative disease.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: November 1, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Curt R. Freed, Wenbo Zhou
  • Patent number: 9480674
    Abstract: The subject invention provides a method of treating acne in a subject which comprises topically and periodically applying to the subject's acne a composition comprising 3-phenyl-1-benzo[f]chromen-1-one and a pharmaceutically acceptable carrier, wherein the 3-phenyl-1-benzo[f]chromen-1-one is present in an amount effective to treat the subject's acne. The subject invention also provides a method of treating a skin condition associated with abnormal sebum secretion or abnormal sebaceous gland function in a subject, compositions in such methods and a sorting method for identifying agonists of AhR pathway, useful in such methods and compositions.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: November 1, 2016
    Assignee: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire Saurat
  • Patent number: 9480675
    Abstract: Systems and methods are described providing therapeutic preparations of sirtuin inhibitors, such as SIRT1 inhibitors, for stimulating load-induced skeletal muscle growth in the body of a patient. The natural stimulation of SIRT1 activity can be suppressed through increased caloric intake and loading in conjunction with the inhibition of sirtuin activity to improve the inhibitory effect. In addition, known muscle growth promoting agents such as amino acids and hormones can be administered at the same time as the sirtuin inhibitor. The size of the tissue structure to be treated or the body size may be used to determine the therapeutic dose of sirtuin inhibitor. The sirtuin inhibitor and muscle stimulating agents are either locally or systemically delivered at therapeutic doses for the desired effect. The SIRT1 inhibitor Splitomycin is particularly effective.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: November 1, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Andrew Philp, Simon Schenk, Keith Baar
  • Patent number: 9480676
    Abstract: Methods of treating cystic fibrosis by administering a PDE4 inhibitor in combination with one or more cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, including ivacaftor, and/or one or more CFTR correctors, including lumacaftor. Pharmaceutical compositions, dosage forms, and kits suitable for use in methods of the invention are also disclosed.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: November 1, 2016
    Assignee: Celgene Corporation
    Inventors: Peter H. Schafer, Shimon Korish
  • Patent number: 9480677
    Abstract: This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: November 1, 2016
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Jianmin Fu, Jean-Jacques Alexandre Cadieux
  • Patent number: 9480678
    Abstract: Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a cellulose thickening agent. X is a halogen or H.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: November 1, 2016
    Assignees: POLA PHARMA INC., NIHON NOHYAKU CO., LTD.
    Inventors: Takaaki Masuda, Naoto Nishida, Naoko Kobayashi, Hideaki Sasagawa
  • Patent number: 9480679
    Abstract: Described herein are formulations and methods for treating diseases caused by infectious pathogens, including mycobacterium avium complex, mycobacterium tuberculosis, Nocardia, Plasmodium falcium, and Plasmodium berghei.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: November 1, 2016
    Assignee: CEMPRA PHARMACEUTICALS, INC.
    Inventor: Prabhavathi Fernandes
  • Patent number: 9480680
    Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, m) of 100-500 nm, wherein the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc. The emulsion formulations and method of manufacturing significantly improves the stability of clopidogrel over other aqueous based formulations (such as cyclodextrin-based formulations and emulsion made using clopidogrel salt as the starting materials) with respect to chiral degradation, hydrolytic, and thermal degradation.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: November 1, 2016
    Inventor: Jingjun Huang
  • Patent number: 9480681
    Abstract: Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.
    Type: Grant
    Filed: September 5, 2012
    Date of Patent: November 1, 2016
    Assignee: Emcure Pharmaceuticals Limited
    Inventors: Jitendra Mohansingh Baweja, Manoj Kumar Thottasseri, Sandip Tanaji Salunkhe, Mukund Keshav Gurjar, Samit Satish Mehta
  • Patent number: 9480682
    Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: November 1, 2016
    Assignee: Amicus Therapeutics, Inc.
    Inventors: David Lockhart, Jeff Castelli
  • Patent number: 9480683
    Abstract: The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: November 1, 2016
    Assignee: AROG PHARMACEUTICALS, INC.
    Inventor: Vinay K. Jain
  • Patent number: 9480684
    Abstract: The invention provides a method of treating anxiety or a compulsive disorder in a subject comprising administering to the subject a compound having formula 2: or a pharmaceutically acceptable salt or solvate thereof, wherein R, R1, R2, R3, R4, R5, and X are as defined in the specification.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: November 1, 2016
    Assignee: The University of Bath
    Inventors: John Lewis, Stephen Husbands
  • Patent number: 9480685
    Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 1, 2016
    Assignee: Purdue Pharma L.P.
    Inventors: Frank S. Caruso, Huai-Hung Kao
  • Patent number: 9480686
    Abstract: The present invention provides a heterocyclic compound represented by the general formula (1): The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 1, 2016
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Yamashita, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Hideaki Kuroda, Haruka Takahashi, Satoshi Shimizu, Tatsuyoshi Tanaka
  • Patent number: 9480687
    Abstract: The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below. X1 to X4 of the compounds of Formulas I and II may be characterized as electron withdrawing groups. In contrast, Y1 to Y4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: November 1, 2016
    Assignee: MEDIBEACON, INC.
    Inventors: Raghavan Rajagopalan, Richard B. Dorshow, William L. Neumann
  • Patent number: 9480688
    Abstract: A composition comprising Androstenone is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the Androstenone is a naturally occurring pheromone.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: November 1, 2016
    Assignee: Sergeant's Pet Care Products, Inc.
    Inventors: Mark Levin, John J. McGlone
  • Patent number: 9480689
    Abstract: The present disclosure provides for compositions and methods of stimulating reproductive behavior and reproductive success and productivity in a suid, such as pigs. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 1, 2016
    Assignee: Animal Biotech, LLC
    Inventor: John J. McGlone
  • Patent number: 9480690
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 1, 2016
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Patent number: 9480691
    Abstract: A liquid medicament for use on skin, epithelium, epidermis, body surface and so on containing a refined peanut oil and, for example, at least one agent which minimizes cell growth, inflammation or both.
    Type: Grant
    Filed: February 29, 2012
    Date of Patent: November 1, 2016
    Assignee: Hill Dermaceuticals, Inc.
    Inventor: Jerry Roth
  • Patent number: 9480692
    Abstract: Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: November 1, 2016
    Assignee: Virginia Commonwealth University
    Inventor: Shunlin Ren
  • Patent number: 9480693
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 1, 2016
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • Patent number: 9480694
    Abstract: There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: November 1, 2016
    Assignee: Syntrix Biosystems, Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 9480695
    Abstract: The invention provides a method for producing an orexin neuron by culturing a pluripotent stem cell or a neural progenitor cell in the presence of N-acetyl-D-mannosamine and optionally in the presence of at least one inhibitor selected from the group consisting of a Sirtuin 1 inhibitor and an O-linked ?-N-acetylglucosamine transferase inhibitor. The invention also provides a therapeutic agent for narcolepsy or eating disorders, such as anorexia, containing N-acetyl-D-mannosamine, which is based on the induction of orexin neuron in vivo.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: November 1, 2016
    Assignee: The University of Tokyo
    Inventors: Kunio Shiota, Shintaro Yagi, Koji Hayakawa, Mitsuko Hirosawa-Takamori, Daisuke Arai, Keiji Hirabayashi
  • Patent number: 9480696
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: November 1, 2016
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Patent number: 9480697
    Abstract: The disclosure relates to an edible energy composition that includes a methylated xanthine, a choline derivative and a flavorant.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: November 1, 2016
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 9480698
    Abstract: Oligonucleotide analogs are provided that incorporate 5-aza-cytosine in the oligonucleotide sequence, e.g., in the form of 5-aza-2?-deoxycytidine (decitabine) or 5-aza-cytidine. In particular, oligonucleotide analogs rich in decitabine-deoxyguanosine islets (DpG and GpD) are provided to target the CpG islets in the human genome, especially in the promoter regions of genes susceptible to aberrant hypermethylation. Such analogs can be used for modulation of DNA methylation, such as effective inhibition of methylation of cytosine at the C-5 position. Methods for synthesizing these oligonucleotide analogs and for modulating nucleic acid methylation are provided. Also provided are phosphoramidite building blocks for synthesizing the oligonucleotide analogs, methods for synthesizing, formulating and administering these compounds or compositions to treat conditions, such as cancer and hematological disorders.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: November 1, 2016
    Assignee: ASTEX PHARMACEUTICALS, INC.
    Inventors: Pasit Phiasivongsa, Sanjeev Redkar
  • Patent number: 9480699
    Abstract: Provided are methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. Also provided are methods for determining the efficacy of a cancer therapy in a subject, methods for diagnosing cancer, methods for assessing patient prognosis, and methods for inducing apoptosis of a cell.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 1, 2016
    Assignee: The Ohio State University Research Foundation
    Inventors: Carlo M. Croce, George A. Calin
  • Patent number: 9480700
    Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: November 1, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Nai-Kong V. Cheung
  • Patent number: 9480701
    Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Stefania Tiddia, Lino Liverani
  • Patent number: 9480702
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • Patent number: 9480703
    Abstract: A composition that includes a nanoparticle. The nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH). The shell includes poly L-arginine. The SNACH is ionically or covalently bonded to the poly L-arginine. A method for treating a disorder of a subject includes: administering to the subject a therapeutically effective amount of the composition for treating the disorder. The disorder is a vascular disorder, a complication of the vascular disorder, or a combination thereof.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 1, 2016
    Inventor: Shaker A. Mousa
  • Patent number: 9480704
    Abstract: The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: November 1, 2016
    Assignee: Cosmederm Bioscience, Inc.
    Inventor: Gary S. Hahn
  • Patent number: 9480705
    Abstract: The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as Staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a site of infection, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9480706
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9480707
    Abstract: The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9480708
    Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9480709
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9480710
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: November 1, 2016
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone